Oncolytics (ONCY) Shares Up 15% Pre-Market Amid REOLYSIN(R) Data
Tweet
Share
E-mailGet Alerts ONCY Hot Sheet
Join SI Premium – FREE
Shares of Oncolytics Biotech (Nasdaq: ONCY) are up more than 15 percent in pre-market action following data from a translational clinical trial which shows REOLYSIN(R) may be used to target tumors.
The stock last traded at $6.32.
Click here to see full details from the press release.
The stock last traded at $6.32.
Click here to see full details from the press release.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Oncolytics Biotech (ONCY) PT Lowered to $5 at H.C. Wainwright
- Real and RE/MAX Holdings receive court approval for merger
- Home Depot expands executive roles, grants $500K in restricted stock
Create E-mail Alert Related Categories
Corporate News, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
